Together with our in vitro finding that MCL-1 plays a predominant role in maintaining osteosarcoma cell survival, as it does in many other types of cancers, our in vivo data highlight the clinical potential of the combining MCL-1 inhibition with regorafenib in the treatment of metastatic osteosarcoma. The gene discussed is MCL1; the disease is cancer.